Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 454 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis(ALS) Clear all
Completed Phase 1Phase 2 Interventional

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

NCT00140218
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrate
Drug
Lead sponsor
Bennett, James P., Jr., M.D., Ph.D.
Individual
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

NCT04993755
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions
TPN-101, 400 mg/day, Placebo
Drug
Lead sponsor
Transposon Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
La Jolla, California • Orange, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Not yet recruiting Not applicable Interventional

Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro

NCT07209943
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
Interventions
Cognixion + Apple Vision Pro
Device
Lead sponsor
Cognixion
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 14, 2026, 7:09 AM EDT
Completed No phase listed Observational

Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis

NCT00339976
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Results available

Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis

NCT03241784
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Autologous T-regulatory lymphocytes, Interleukin-2
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NP001, Placebo
Drug
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 14, 2026, 7:09 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

NCT01459302
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

NCT01994109
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC, PLACEBO
Drug · Other
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
24
States / cities
Loma Linda, California • Los Angeles, California • National City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Impact of Nuedexta on Bulbar Physiology and Function in ALS

NCT03883581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
dextromethorphan HBr and quinidine sulfate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS

NCT02469675
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Amyotrophic Lateral Sclerosis (ALS)
Interventions
Transcranial magnetic stimulation, Median nerve stimulation, Cervical transcutaneous stimulation
Device
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 14, 2026, 7:09 AM EDT
Completed No phase listed Observational

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation

NCT01925196
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 14, 2026, 7:09 AM EDT
Not listed Phase 3 Interventional

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

NCT00069186
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Creatine Monohydrate
Drug
Lead sponsor
The Avicena Group
Industry
Eligibility
21 Years to 80 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

NCT04632225
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Precise Robotically IMplanted Brain-Computer InterfacE

NCT06429735
View directory record Official record
Conditions
Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis
Interventions
N1 Implant, R1 Robot
Device
Lead sponsor
Neuralink Corp
Industry
Eligibility
22 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Phoenix, Arizona • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intermuscular Coherence as a Biomarker for ALS

NCT05104710
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
4
States / cities
Irvine, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 14, 2026, 7:09 AM EDT
Terminated Phase 2 Interventional Results available

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
L-Serine
Drug
Lead sponsor
Elijah W. Stommel
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 14, 2026, 7:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS

NCT03851302
View directory record Official record
Conditions
Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Interventions
Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning, Isometric hand exercise
Other
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041
View directory record Official record
Conditions
Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
Interventions
Placement of the BrainGate2 sensor(s) into the motor-related cortex
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2038
U.S. locations
6
States / cities
Sacramento, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 7:09 AM EDT